These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 35674097)

  • 1. Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II-IIIA NSCLC patients.
    Vessies DCL; Schuurbiers MMF; van der Noort V; Schouten I; Linders TC; Lanfermeijer M; Ramkisoensing KL; Hartemink KJ; Monkhorst K; van den Heuvel MM; van den Broek D
    Mol Oncol; 2022 Jul; 16(14):2719-2732. PubMed ID: 35674097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
    Xia L; Mei J; Kang R; Deng S; Chen Y; Yang Y; Feng G; Deng Y; Gan F; Lin Y; Pu Q; Ma L; Lin F; Yuan Y; Hu Y; Guo C; Liao H; Liu C; Zhu Y; Wang W; Liu Z; Xu Y; Li K; Li C; Li Q; He J; Chen W; Zhang X; Kou Y; Wang Y; Wu Z; Che G; Chen L; Liu L
    Clin Cancer Res; 2022 Aug; 28(15):3308-3317. PubMed ID: 34844976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics.
    Wang S; Xia Z; You J; Gu X; Meng F; Chen P; Tang W; Bao H; Zhang J; Wu X; Shao Y; Wang J; Zuo X; Xu L; Yin R
    Cancer Res Commun; 2023 May; 3(5):933-942. PubMed ID: 37377889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.
    Tan AC; Lai GGY; Saw SPL; Chua KLM; Takano A; Ong BH; Koh TPT; Jain A; Tan WL; Ng QS; Kanesvaran R; Rajasekaran T; Kalashnikova E; Renner D; Sudhaman S; Malhotra M; Sethi H; Liu MC; Aleshin A; Lim WT; Tan EH; Skanderup AJ; Ang MK; Tan DSW
    Cancer; 2024 May; 130(10):1758-1765. PubMed ID: 38422026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.
    Gale D; Heider K; Ruiz-Valdepenas A; Hackinger S; Perry M; Marsico G; Rundell V; Wulff J; Sharma G; Knock H; Castedo J; Cooper W; Zhao H; Smith CG; Garg S; Anand S; Howarth K; Gilligan D; Harden SV; Rassl DM; Rintoul RC; Rosenfeld N
    Ann Oncol; 2022 May; 33(5):500-510. PubMed ID: 35306155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [MinerVa: A high performance bioinformatic algorithm for the detection of minimal residual disease in solid tumors].
    Yang P; Zhang Y; Xia L; Mei J; Fan R; Huang Y; Liu L; Chen W
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2023 Apr; 40(2):313-319. PubMed ID: 37139763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor DNA minimal residual disease in clinical practice of non-small cell lung cancer.
    Xia J; Zhang J; Xiong Y; Zhao J; Zhou Y; Jiang T; Zhu J
    Expert Rev Mol Diagn; 2023; 23(10):913-924. PubMed ID: 37702546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer.
    Jung HA; Ku BM; Kim YJ; Park S; Sun JM; Lee SH; Ahn JS; Cho JH; Kim HK; Choi YS; Choi YL; Shin SH; Jeong BH; Um SW; Kim H; Kim K; Ahn MJ; Kim J
    J Thorac Oncol; 2023 Sep; 18(9):1199-1208. PubMed ID: 37308037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer.
    Ryoo SB; Heo S; Lim Y; Lee W; Cho SH; Ahn J; Kang JK; Kim SY; Kim HP; Bang D; Kang SB; Yu CS; Oh ST; Park JW; Jeong SY; Kim YJ; Park KJ; Han SW; Kim TY
    Br J Cancer; 2023 Aug; 129(2):374-381. PubMed ID: 37280413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
    Shields MD; Chen K; Dutcher G; Patel I; Pellini B
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor DNA-minimal residual disease: An up-and-coming nova in resectable non-small-cell lung cancer.
    Li FQ; Cui JW
    Crit Rev Oncol Hematol; 2022 Nov; 179():103800. PubMed ID: 36031171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer.
    Chen K; Yang F; Shen H; Wang C; Li X; Chervova O; Wu S; Qiu F; Peng D; Zhu X; Chuai S; Beck S; Kanu N; Carbone D; Zhang Z; Wang J
    Cancer Cell; 2023 Oct; 41(10):1749-1762.e6. PubMed ID: 37683638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.
    Zhong R; Gao R; Fu W; Li C; Huo Z; Gao Y; Lu Y; Li F; Ge F; Tu H; You Z; He J; Liang W
    BMC Med; 2023 May; 21(1):180. PubMed ID: 37173789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer.
    Wang S; Li M; Zhang J; Xing P; Wu M; Meng F; Jiang F; Wang J; Bao H; Huang J; Ren B; Yu M; Qiu N; Li H; Yuan F; Zhang Z; Jia H; Lu X; Zhang S; Wang X; Xu Y; Xia W; Liu T; Xu W; Xu X; Sun M; Wu X; Shao Y; Wang Q; Dai J; Qiu M; Wang J; Zhang Q; Xu L; Shen H; Yin R
    J Hematol Oncol; 2022 Oct; 15(1):137. PubMed ID: 36183093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.
    Oh Y; Yoon SM; Lee J; Park JH; Lee S; Hong T; Chung LI; Sudhaman S; Riddell T; Palsuledesai CC; Krainock M; Liu MC; Chae YK
    Thorac Cancer; 2024 May; 15(13):1095-1102. PubMed ID: 38558374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Application Value of ctDNA-based MRD Dedection 
in Early Stage Non-small Cell Lung Cancer after Radical Surgery].
    Dou S; Xie H; Yang L
    Zhongguo Fei Ai Za Zhi; 2021 Dec; 24(12):862-866. PubMed ID: 34743498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer.
    Abbosh C; Hodgson D; Doherty GJ; Gale D; Black JRM; Horn L; Reis-Filho JS; Swanton C
    Trends Cancer; 2024 Jul; 10(7):643-654. PubMed ID: 38839544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic potential of circulating tumor DNA detection at different time periods in resectable non-small cell lung cancer: Evidence from a meta-analysis.
    Wang B; Pei J; Wang S; Cheng K; Yu J; Liu J
    Crit Rev Oncol Hematol; 2022 Sep; 177():103771. PubMed ID: 35905822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.
    Abbosh C; Birkbak NJ; Swanton C
    Nat Rev Clin Oncol; 2018 Sep; 15(9):577-586. PubMed ID: 29968853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non-small cell lung cancer.
    Tian X; Liu X; Wang K; Wang R; Li Y; Qian K; Wang T; Zhao X; Liu L; Zhang PL; Xiong Y; Rui J; Chen R; Zhang Y
    Thorac Cancer; 2024 Apr; 15(10):797-807. PubMed ID: 38409945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.